Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RZL-012 + lidocaine
- Development stage
- Unknown
- Lead developer
- Raziel Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
RZL-012 is a novel investigational small molecule (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) developed for subcutaneous injection to reduce localized fat. Its mechanism of action involves direct disruption of adipocyte cell membrane integrity, leading to adipocyte death (liponecrosis), followed by an inflammatory response and replacement of dead fat tissue with fibrotic tissue. This process results in significant reduction in fat volume at the treated site[1][6][8]. RZL-012 is being studied for conditions such as submental fat, obesity, and Dercum disease (adiposis dolorosa). In some clinical trials, RZL-012 is administered with lidocaine (a local anesthetic) to improve patient comfort during injection[4]. The drug is under development by Raziel Therapeutics and Yissum Research Development Company[3].
- Other names
- tapencarium + lidocaine
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on RZL-012 + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RZL-012 + lidocaine.